7EP6
Engineered Hepatitis B virus core antigen T=4
7EP6 の概要
エントリーDOI | 10.2210/pdb7ep6/pdb |
EMDBエントリー | 31234 |
分子名称 | Capsid protein,Immunoglobulin G-binding protein A (1 entity in total) |
機能のキーワード | cancer therapy, epidermal growth factor receptor 1, affibody, virus like particle |
由来する生物種 | Hepatitis B virus genotype C subtype adr (strain Japan/adr4/1983) (HBV-C) 詳細 |
タンパク質・核酸の鎖数 | 4 |
化学式量合計 | 147212.31 |
構造登録者 | |
主引用文献 | Heo, Y.,Jeong, H.,Yoo, Y.,Yun, J.H.,Ryu, B.,Cha, Y.J.,Lee, B.R.,Jeon, Y.E.,Kim, J.,Jeong, S.,Jo, E.,Woo, J.S.,Lee, J.,Cho, H.S.,Lee, W. Structural and Functional Characterizations of Cancer Targeting Nanoparticles Based on Hepatitis B Virus Capsid. Int J Mol Sci, 22:-, 2021 Cited by PubMed Abstract: Cancer targeting nanoparticles have been extensively studied, but stable and applicable agents have yet to be developed. Here, we report stable nanoparticles based on hepatitis B core antigen (HBcAg) for cancer therapy. HBcAg monomers assemble into spherical capsids of 180 or 240 subunits. HBcAg was engineered to present an affibody for binding to human epidermal growth factor receptor 1 (EGFR) and to present histidine and tyrosine tags for binding to gold ions. The HBcAg engineered to present affibody and tags (HAF) bound specifically to EGFR and exterminated the EGFR-overexpressing adenocarcinomas under alternating magnetic field (AMF) after binding with gold ions. Using cryogenic electron microscopy (cryo-EM), we obtained the molecular structures of recombinant HAF and found that the overall structure of HAF was the same as that of HBcAg, except with the affibody on the spike. Therefore, HAF is viable for cancer therapy with the advantage of maintaining a stable capsid form. If the affibody in HAF is replaced with a specific sequence to bind to another targetable disease protein, the nanoparticles can be used for drug development over a wide spectrum. PubMed: 34502049DOI: 10.3390/ijms22179140 主引用文献が同じPDBエントリー |
実験手法 | ELECTRON MICROSCOPY (3.86 Å) |
構造検証レポート
検証レポート(詳細版)をダウンロード